Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Feldman

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Health Affairs (Project Hope)|May 17, 2022
Understanding 'Evergreening': Making Minor Modifications Of Existing Medications To Extend ProtectionsRobin Feldman
Journal of Alzheimer'S Disease : JAD|April 12, 2021
Physicians Treating Alzheimer's Disease Patients Should Be Aware that Televised Direct-to-Consumer Advertising Links More Strongly to Drug Utilization in Older PatientsRobin Feldman
Stanford Law Review|July 22, 2011
Whose body is it anyway? Human cells and the strange effects of property and intellectual property lawRobin Feldman
Journal of Law and the Biosciences|May 31, 2019
May your drug price be evergreenRobin Feldman
JAMA Internal Medicine|August 7, 2023
CalRx Biosimilar Insulin: California's Initiative to Enter the Insulin MarketRobin Feldman
Journal of Law and the Biosciences|May 14, 2021
The devil in the tiersRobin Feldman
Journal of Law and the Biosciences|December 14, 2023
Leading with the trailing edge: facilitating patient choice for insulin productsRobin Feldman
Plos Medicine|April 25, 2024
Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars ActRobin Feldman
Stanford Technology Law Review : STLR : an Online High-Technology Law Journal From Stanford Law School|September 16, 2014
Copyright at the Bedside: Should We Stop the Spread?Robin Feldman, John Newman
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 4, 2024
NIH Licensing Would Benefit from Free-Market ProvisionsRobin Feldman, Zachary Rosen
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Health Affairs (Project Hope)|May 17, 2022
Understanding 'Evergreening': Making Minor Modifications Of Existing Medications To Extend ProtectionsRobin Feldman
Journal of Alzheimer'S Disease : JAD|April 12, 2021
Physicians Treating Alzheimer's Disease Patients Should Be Aware that Televised Direct-to-Consumer Advertising Links More Strongly to Drug Utilization in Older PatientsRobin Feldman
Stanford Law Review|July 22, 2011
Whose body is it anyway? Human cells and the strange effects of property and intellectual property lawRobin Feldman
Journal of Law and the Biosciences|May 31, 2019
May your drug price be evergreenRobin Feldman
JAMA Internal Medicine|August 7, 2023
CalRx Biosimilar Insulin: California's Initiative to Enter the Insulin MarketRobin Feldman
Journal of Law and the Biosciences|May 14, 2021
The devil in the tiersRobin Feldman
Journal of Law and the Biosciences|December 14, 2023
Leading with the trailing edge: facilitating patient choice for insulin productsRobin Feldman
Plos Medicine|April 25, 2024
Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars ActRobin Feldman
Stanford Technology Law Review : STLR : an Online High-Technology Law Journal From Stanford Law School|September 16, 2014
Copyright at the Bedside: Should We Stop the Spread?Robin Feldman, John Newman
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 4, 2024
NIH Licensing Would Benefit from Free-Market ProvisionsRobin Feldman, Zachary Rosen
Pageof 3